Cellectis Touts Positive Preliminary Data From Two Leukemia Trials

Cellectis S.A (NASDAQ:CLLS) highlighted updated clinical data on its Phase 1/2a BALLI-01 trial (evaluating UCART22) and on its Phase 1 AMELI-01…
  • Cellectis S.A (NASDAQ:CLLS) highlighted updated clinical data on its Phase 1/2a BALLI-01 trial (evaluating UCART22) and on its Phase 1 AMELI-01 trial (evaluating UCART123).
  • Compared to the last clinical update on BALLI-01 at ASH 2021, the presented data comes from five additional patients who received UCART22 at dose level 3 (DL3) 5×106 cells/kg after lymphodepletion with FCA. 
  • Evidence of UCART22 anti-tumor activity was observed in 60% (n=3) of the five patients.
  • A patient experienced a durable, minimal residual disease (MRD) negative complete response with incomplete count recovery (CRi) that continues beyond six months.
  • The company also shared preliminary data from patients who received UCART123.
  • The FCA LD regimen resulted in robust lymphodepletion for greater than 28 days in all patients. Seven out of nine patients demonstrated UCART123 expansion.
  • Two out of eight patients (25%) at DL2 with the FCA arm achieved a meaningful response.
  • A patient with stable disease achieved greater than 90% bone marrow blast reduction (60% to 5%) at Day 28.
  • Price Action: CLLS shares are up 8.52% at $2.42 on the last check Tuesday.
  • Photo Via Company
Total
0
Shares
Related Posts
Read More

CBD-Focused Avicanna Taps Into European Market Via Exclusive Pharma Supply Deal

Canadian cannabinoid-based biopharmaceutical firm Avicanna will supply two proprietary topical products to an unnamed multinational pharmaceutical firm in six European countries in 2024. The deal will commercialise Avicanna's RHO Phyto brand in Europe for the first time. The company praised its own proprietary patent-protected technologies being entered into "the European market without competition" as testament to its "scientific and technical leadership in the cannabinoid clinical and commercialisation field", highlighting the deal's strategic nature and geographic position, as well as the expected rapid expansion into other European countries. The unnamed pharmaceutical company manufactures and markets a wide range of pharmaceuticals across four continents and has established a commercial infrastructure in Europe. These manufacturing plants will produce Avicanna's Ultra-CBD cream and CBG Transdermal Gel in 2024.

AVCNF